stock-detail (SRNE)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/20/2017 12:19 pm

4/19/2017 12:19 pm

4/19/2017 12:19 pm

4/19/2017 12:19 pm

4/12/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial

4/3/2017 05:02 pm

[PR Newswire] - SAN DIEGO, April 3, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), and its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), announced ...

Sorrento and Wildcat Announce Resolution

3/20/2017 12:00 pm

[PR Newswire] - SAN DIEGO, March 20, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNE) (the "Company" or "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Wildcat Capital Management LLC ("Wildcat"), whose clients currently are major holders of the outstanding common stock of Sorrento, today jointly announced that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the Company's private placement agreements announced by the Company in April 2016 ("Inspection Demand Action") and Wildcat's derivative action against the Company and certain members of its Board of Directors filed in May 2016 ("Derivative Action").

Sorrento and Wildcat Announce Resolution

3/20/2017 12:00 pm

[CNW Group] - Sorrento and Wildcat Announce Resolution